The EU MDR/IVDR transition document is no longer the current route
HSA previously issued supplementary guidance specifically for Change Notification applications arising from the European transition to the Medical Device Regulation and In Vitro Diagnostic Medical Devices Regulation. The document addressed the large volume of consequential changes expected for devices already registered in Singapore, particularly updates to labels and instructions for use.
The November 2023 version stated that the supplementary approach would be effective until the end of 2025. HSA’s current guidance library now lists that document as archived, while the current Change Notification baseline is GN-21 R7.
For registrants making EU-driven changes today, the practical consequence is that the reason for the change — such as alignment with EU MDR or IVDR — does not by itself determine the Singapore CN route. The actual content and regulatory impact of the change must be assessed under current GN-21.
What the former transition arrangement did
The archived supplementary document created a simplified approach for defined EU MDR/IVDR transition changes.
Examples included:
- Certain label and IFU changes with no new safety or performance information did not require a CN submission.
- Material “-Free” claims and some IFU clarifications or additions of safety information could be handled as Change Type 5E Notification Changes when the stated criteria were met.
- Eligible EU MDR/IVDR notification changes could be bundled across registered devices under specified conditions, with submission required within a maximum of six months from first global implementation.
Those provisions were designed for the transition context. They should not be treated as a separate current pathway once the supplementary document has been archived.
How the current GN-21 framework applies
Start with the current list of changes that do not require CN
GN-21 R7 Section 2.3 includes a general list of changes that do not require Change Notification. These include purely presentational labelling changes, certain reference-agency information changes, and some labelling changes that introduce no new safety or performance information.
The current question is therefore whether the proposed change meets the GN-21 exemption criteria, not simply whether it was triggered by EU MDR or IVDR.
Use Flowchart 5 for other labelling changes
Where the change is not exempt, GN-21 R7 Flowchart 5 differentiates changes involving indications for use, warnings and precautions, method of use, IFU rephrasing, and other labelling changes.
Depending on what changes and the device risk class, the result may be a Notification, Review, or Technical Change. An EU-driven change is not automatically a low-level notification simply because its origin is regulatory harmonisation.
General Notification bundling remains available
Current GN-21 still permits eligible Notification Changes to be bundled into one CN application or submitted with the next Review or Technical Change, whichever comes first.
Any bundled Notification Change must be submitted within a maximum of six months from its first global implementation. This is now part of the general GN-21 notification framework rather than an EU MDR/IVDR-specific transition route.
What registrants can check now
- Confirm that internal procedures and regulatory-intelligence records no longer treat the archived EU MDR/IVDR supplementary document as current guidance.
- Re-map recurring EU label and IFU changes to GN-21 R7 Section 2.3 and Flowchart 5.
- Review legacy submission templates that may still assume the old transition-specific declaration or classification approach.
- If Notification Changes are being bundled, retain the first global implementation date for each change and control the six-month submission window.
- Escalate changes that affect intended use, device design, performance, or require new validation evidence rather than treating them as routine EU labelling alignment.
The transition document was useful when EU MDR and IVDR created a concentrated wave of consequential changes for products already registered in Singapore. The current regulatory task is different: registrants should classify each ongoing EU-driven change under the current GN-21 framework and use the transition document only as historical context.
Sources
- Primary official sourceGuidance documents for medical devices (opens in a new tab)Health Sciences Authority
- Supporting sourceGN-21-R7 Guidance on Change Notification for Registered Medical Devices (opens in a new tab)Health Sciences Authority
- Supporting sourceChange Notification applications arising from the EU MDR/IVDR related changes to registered medical devices (opens in a new tab)Health Sciences Authority
- Supporting sourceNotify changes to registered medical devices (opens in a new tab)Health Sciences Authority